One year into the COVID pandemic, the first vaccines were just entering the market and there were not yet any therapeutics available. Innovators and their partners had scrambled to develop COVID vaccines - including with novel platforms - more quickly than ever before in history. Globally distributed networks for producing Vx and Tx were just being established. This report, based on interviews with senior leaders at the innovative biopharma companies leading the fight against COVID, captures the story of innovation, IP, and COVID.